Compare · RVTY vs TXG
RVTY vs TXG
Side-by-side comparison of Revvity Inc. (RVTY) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $10.97B, about 2.8x TXG ($3.94B).
- Over the past year, RVTY is up 9.2% and TXG is up 193.4% - TXG leads by 184.2 points.
- TXG has been more active in the news (3 items in the past 4 weeks vs 2 for RVTY).
- TXG has more recent analyst coverage (25 ratings vs 19 for RVTY).
- Company
- Revvity Inc.
- 10x Genomics Inc.
- Price
- $101.39+3.00%
- $29.61-4.62%
- Market cap
- $10.97B
- $3.94B
- 1M return
- +2.55%
- +32.22%
- 1Y return
- +9.17%
- +193.37%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 2
- 3
- Recent ratings
- 19
- 25
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)
Latest TXG
- Chief Executive Officer Saxonov Serge sold $709,057 worth of shares (28,893 units at $24.54) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,138,380 units (SEC Form 4) to satisfy withholding tax
- Officer Hindson Benjamin J. sold $283,399 worth of shares (11,595 units at $24.44), decreasing direct ownership by 2% to 502,000 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Taich Adam sold $369,018 worth of shares (15,098 units at $24.44), decreasing direct ownership by 4% to 379,898 units (SEC Form 4) to cover taxes
- 10x Genomics Reports First Quarter 2026 Financial Results
- 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
- The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
- SEC Form DEFA14A filed by 10x Genomics Inc.
- SEC Form DEF 14A filed by 10x Genomics Inc.
- 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood